Archives

On behalf of those impacted by Alzheimer’s disease, the Alzheimer’s Association enthusiastically welcomes today’s historic FDA approval of aducanumab (Biogen/Eisai) for the treatment of [...]

The FDA’s approval of the Biogen-Eisai drug, aducanumab, marks a milestone achievement in Alzheimer’s disease research. This drug is the first approved treatment shown to slow the progression of [...]